drugset
drugset / Trial / NCT01173081

The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures

NCT01173081 ↗

Phase 4 Unknown 38 enrolled Ohio Orthopedic Center of Excellence Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This randomized, placebo-controlled study will evaluate the effectiveness of the adjunctive use of teriparatide for the healing of Jones fractures.

Timeline

Start
2010-07
Primary completion
2014-04
Completion
2014-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Teriparatide Protein / enzyme biologic 20 ug —

Indications

No indication recorded.